Clinical study of ultra-early trans-neuroendoscopic treatment of hypertensive cerebral haemorrhage in the basal ganglia region

doi:10.3877/cma.j.issn.2095-123X.2022.03.004

Abstract

Abstract:

Objective

To observe the clinical effect of early treatment of hypertensive intracerebral hemorrhage in basal ganglia area by neuroendoscope.

Methods

Forty-five patients with hypertensive intracerebral hemorrhage in the basal ganglia region who received ultra early (within 7 h) neuroendoscopic hematoma removal in Neurosurgery Department of Bozhou People’s Hospital from January 2018 to September 2019 were selected as the study group. At the same time, 44 patients who received neuroendoscopic hematoma removal within 7-24 h of intracerebral hemorrhage matched with the baseline data of the study group were selected as the control group. The postoperative rebleeding rate, hematoma clearance rate, complication rate, GCS, NIHSS and Barthel scores were compared between the control group and the study group.

Results

There was no significant difference in rebleeding rate, hematoma clearance rate, intracranial hematoma, intracranial infection and pulmonary infection between two groups (P>0.05). The GCS and Barthel scores of the study group at 3 and 7 d afteroperation were higher than those of the control group (P<0.05); NIHSS scores in the study group at 3 and 7 d after operation was lower than that in the control group (P<0.05).

Conclusion

Compared with surgery 7-24 h after intracerebral hemorrhage, neuroendoscopic surgery within 7 h after intracerebral hemorrhage has a more significant effect on the improvement of postoperative nerve damage and quality of life.

Key words: Cerebral hemorrhage, Ultra-early, Basal ganglia, Neuroendoscopy

Shuai Niu, Qihai Zhu. Clinical study of ultra-early trans-neuroendoscopic treatment of hypertensive cerebral haemorrhage in the basal ganglia region[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(03): 142-145.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2022.03.004

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2022/V12/I03/142

Figures/Tables 3

References 16

[1]	Rass V, Helbok R. Early brain injury after poor-grade subarachnoid hemorrhage[J]. Curr Neurol Neurosci Rep, 2019, 19(10): 78.
[2]	肖志朋,崔雨迪,潘耀华,等.血管内栓塞颅内微小动脉瘤的临床疗效分析:单中心前瞻性研究[J].中国脑血管病杂志, 2021, 18(1): 25-29.
[3]	崔冬强,冯铭,束旭俊,等.增强现实技术辅助神经内镜与小骨窗开颅血肿清除术治疗高血压脑出血疗效分析[J].中国现代神经疾病杂志, 2019, 19(9): 654-660.
[4]	Van Ornam J, Pruitt P, Borczuk P. Is repeat head CT necessary in patients with mild traumatic intracranial hemorrhage[J]. Am J Emerg Med, 2019, 37(9): 1694-1698.
[5]	唐海涛,鞠盛国,陈刚,等.神经内窥镜与穿刺引流术治疗基底节区自发性高血压脑出血的临床比较[J].中国实用医药, 2018, 13(25): 16-18.
[6]	侯晓鹏,范益民,刘晓东,等.经侧裂-岛叶入路早期显微手术治疗基底节区脑出血体会[J].中国医学创新, 2014, 11(14): 131-133.
[7]	中国急诊急救神经内镜治疗高血压性脑出血协作组,中国医药教育协会神经内镜与微创医学专业委员会,中华医学会神经外科分会. 2020神经内镜下高血压性脑出血手术治疗中国专家共识[J].中华医学杂志, 2020, 100(33): 2579-2585.
[8]	杜涛明. MSCT在预测高血压脑出血早期血肿扩大中的临床价值[J].现代临床医学, 2019, 45(5): 352-353.
[9]	邹滔滔.内镜辅助下高血压脑出血微创手术治疗的临床疗效探讨[J].基层医学论坛, 2019, 23(28): 4061-4062.
[10]	刘志学,张晓燕,马丽红.基底节高压性脑出血MSCT分级与其预后的相关性分析[J].中国CT和MRI杂志, 2019, 17(9): 14-16, 79.
[11]	李振勇,雷昆,胡波,等.不同时间手术治疗高血压脑出血的临床效果比较[J].临床合理用药杂志, 2019, 14(26): 108-112.
[12]	Vales-Montero M, García-Pastor A, Iglesias-Mohedano AM, et al. Cerebral amyloid angiopathy-related transient focal neurological episodes: a transient ischemic attack mimic with an increased risk of intracranial hemorrhage[J]. J Neurol Sci, 2019, 406: 116452.
[13]	Hernández-Durán S, Mielke D, Rohde V, et al. Does nimodipine interruption due to high catecholamine doses lead to a greater incidence of delayed cerebral ischemia in the setting of aneurysmal subarachnoid hemorrhage?[J]. World Neurosurg, 2019, 132: e834-e840.
[14]	Kaiser J, Schebesch KM, Brawanski A, et al. Long-term follow-up of cerebral amyloid angiopathy-associated intracranial hemorrhage reveals a high prevalence of atrial fibrillation[J]. J Stroke Cerebrovasc Dis, 2019, 28(11): 104342.
[15]	侯国勇.早期强化降压联合尼莫地平治疗高血压脑出血临床疗效观察[J].医药论坛杂志, 2019, 40(01): 36-38.
[16]	季占胜.超早期强化降压治疗对脑出血血肿扩大、血浆MMP-9及神经功能的影响[J].中外医疗, 2018, 37(2): 60-62.

组别	例数	性别（男/女）	年龄（岁，Mean±SD）	平均收缩压（mmHg，Mean±SD）	体质量指数（Mean±SD）	出血量（mL，Mean±SD）	GCS评分（分，Mean±SD）
研究组	45	21/24	57.41±8.12	160.25±14.54	25.02±3.49	63.55±11.62	6.25±1.71
对照组	44	20/24	57.02±8.33	162.43±13.83	25.54±3.75	65.80±10.34	6.63±1.59
t/χ²值		1.021	0.011	2.236	4.175	0.964	1.085
P值		0.652	0.917	0.135	0.041	0.364	0.298

组别	例数	性别（男/女）	年龄（岁，Mean±SD）	平均收缩压（mmHg，Mean±SD）	体质量指数（Mean±SD）	出血量（mL，Mean±SD）	GCS评分（分，Mean±SD）
研究组	45	21/24	57.41±8.12	160.25±14.54	25.02±3.49	63.55±11.62	6.25±1.71
对照组	44	20/24	57.02±8.33	162.43±13.83	25.54±3.75	65.80±10.34	6.63±1.59
t/χ²值		1.021	0.011	2.236	4.175	0.964	1.085
P值		0.652	0.917	0.135	0.041	0.364	0.298

组别	例数	再出血率	血肿清除率	并发症
组别	例数	再出血率	血肿清除率	颅内血肿	颅内感染	肺部感染
对照组	44	1（2.22）	37（84.09）	3（6.81）	2（4.54）	3（6.81）
研究组	45	4（8.89）	43（95.56）	1（2.22）	0（0.00）	1（2.22）
χ²值		0.820	2.080	0.280	0.530	0.280
P值		0.365	0.149	0.597	0.467	0.597

组别	例数	再出血率	血肿清除率	并发症
组别	例数	再出血率	血肿清除率	颅内血肿	颅内感染	肺部感染
对照组	44	1（2.22）	37（84.09）	3（6.81）	2（4.54）	3（6.81）
研究组	45	4（8.89）	43（95.56）	1（2.22）	0（0.00）	1（2.22）
χ²值		0.820	2.080	0.280	0.530	0.280
P值		0.365	0.149	0.597	0.467	0.597

组别	例数	GCS评分		NIHSS评分		Barthel评分
组别	例数	术后3 d	术后7 d	术后3 d	术后7 d	术后3 d	术后7 d
对照组	44	8.01±1.90	11.15±2.28	18.83±5.04	12.21±4.22	26.18±6.40	44.13±7.72
研究组	45	10.63±2.06	13.67±2.57	14.50±4.62	8.51±3.68	38.40±7.12	51.29±8.70
t值		5.260	5.896	4.227	4.411	9.509	10.103
P值		0.022	0.015	0.040	0.036	0.002	0.002

Please choose a citation manager

Content to export